Johnson & Johnson’s (NYSE:JNJ) Biosense Webster said yesterday it launched its Carto Vizigo bi-directional guiding sheath designed for use with the company’s Carto 3 system in the US.
The Irvine, Calif.-based division said that the sheath is designed for use with the Carto 3 system during catheter ablation procedures to aid electrophysiologists in reducing fluoroscopy dependency and to reduce radiation exposure.
“We are committed to developing novel technologies and workflows for EPs to reduce their exposure to radiation and help them gain freedom from the orthopedic burden of lead. The Vizigo sheath represents the next step in optimizing the Carto 3 System experience and enhancing the benefits our customers can reap from our integrated platform of technologies,” J&J medical devices cardiovascular and specialty solutions group chair Shlomi Nachman said in a press release.
The newly launched Carto Vizigo can be visualized on the Carto3 system map during ablation procedures, which the company said eliminates the need to solely use fluoroscopy to track its location.
The system has already been used in its first commercial procedures at the Massachusetts General Hospital in Boston, Biosense Webster said.
“We are always looking for ways to improve the care we deliver to our patients. One of our overall goals is to reduce dependency on fluoroscopy and gain more directional control and awareness during procedures,” MGH atrial fibrillation program director Dr. Moussa Mansour said in a prepared statement.
Last week, Biosense Webster said that it launched a European trial of its Qdot Micro novel radiofrequency ablation catheter designed for treating paroxysmal atrial fibrillation.
